c-MET (L1195V)

MET · Variant type: point · HGVS: p.L1195V

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	93.2%	6.8%	88.97
2	Tepotinib	75.5%	24.5%	99.75
3	Pacritinib	75.1%	24.9%	88.64
4	Capmatinib	68.4%	31.6%	99.75
5	Repotrectinib	54.2%	45.8%	84.21
6	Defactinib	48.5%	51.5%	92.68
7	Tivozanib	41.5%	58.5%	92.42
8	Neratinib	36.7%	63.3%	93.18
9	Selpercatinib	33.4%	66.6%	96.72
10	Sunitinib	32.3%	67.7%	91.73
11	Fedratinib	31.9%	68.1%	96.21
12	Cobimetinib	21.8%	78.2%	100.00
13	Deucravacitinib	20.5%	79.5%	98.99
14	Pexidartinib	19.1%	80.9%	99.49
15	Entrectinib	17.5%	82.5%	93.69
16	Futibatinib	12.9%	87.1%	98.48
17	Canertinib	11.9%	88.1%	96.49
18	Erdafitinib	9.7%	90.3%	95.71
19	Capivasertib	9.4%	90.6%	96.48
20	Asciminib	8.7%	91.3%	100.00
21	Alpelisib	8.5%	91.5%	97.22
22	Vandetanib	6.9%	93.1%	95.74
23	Avapritinib	6.9%	93.1%	97.73
24	Pralsetinib	6.8%	93.2%	93.43
25	Lazertinib	6.4%	93.6%	97.47

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	93.2%	—	—
Tepotinib	75.5%	—	—
Pacritinib	75.1%	—	—
Capmatinib	68.4%	—	—
Repotrectinib	54.2%	—	—
Defactinib	48.5%	—	—
Tivozanib	41.5%	—	—
Neratinib	36.7%	—	—
Selpercatinib	33.4%	—	—
Sunitinib	32.3%	—	—
Fedratinib	31.9%	—	—
Cobimetinib	21.8%	—	—
Deucravacitinib	20.5%	—	—
Pexidartinib	19.1%	—	—
Entrectinib	17.5%	—	—
Futibatinib	12.9%	—	—
Canertinib	11.9%	—	—
Erdafitinib	9.7%	—	—
Capivasertib	9.4%	—	—
Asciminib	8.7%	—	—
Alpelisib	8.5%	—	—
Vandetanib	6.9%	—	—
Avapritinib	6.9%	—	—
Pralsetinib	6.8%	—	—
Lazertinib	6.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms